ClinicaliQ Trial Snapshot
- A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez — Recruiting • Oncology • NCT06423573.
- Treatment Being Tested: Filsuvez (a topical gel) is being assessed for its potential to reduce skin cancer incidence in epidermolysis bullosa patients by promoting proper collagen formation and improving skin integrity.
- Patient Eligibility Overview: The study targets patients with epidermolysis bullosa—a genetic condition causing fragile skin with impaired collagen formation—who have significantly elevated baseline risk of developing skin cancers.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
In patients with epidermolysis bullosa (EB), collagen does not form properly, so their skin is very fragile and blisters easily. Such patients are also at greatly increased risk of developing skin cancers. Filsuvez is a topical gel used to promote healing of skin lesions in patients with certain types of EB. In this observational study, patients with either dystrophic EB (DEB) or junctional EB (JEB) will receive standard of care treatment, whether Filsuvez or something else, and will be followed for a minimum of 3 years. The main purpose is…
Eligibility Snapshot
- : * Patients with a confirmed diagnosis of dystrophic EB or junctional EB
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.